

SUBJECT INDEX TO VOLUME 1

<p>Adenocarcinoma <i>in situ</i> (AIS) 186</p> <p style="padding-left: 20px;">cold knife conization (CKC) for 187</p> <p style="padding-left: 20px;">endocervical curettage (ECC) for 187</p> <p style="padding-left: 20px;">fertility-sparing surgery for 187</p> <p style="padding-left: 20px;">hysterectomy for 187</p> <p style="padding-left: 20px;">microinvasive (stage IA₁/IA₂) of 188</p> <p style="padding-left: 20px;">post-conization surveillance of 187</p> <p style="padding-left: 20px;">recurrent type 187</p> <p>Advanced (stage IIB-IVA) cervical adenocarcinoma 191</p> <p style="padding-left: 20px;">experimental treatment for 192</p> <p style="padding-left: 20px;">neoadjuvant chemotherapy for 192</p> <p style="padding-left: 20px;">pretreatment surgical staging for 191</p> <p style="padding-left: 20px;">primary platinum-based chemo-radiation for 191</p> <p>Amino acid transporter 163</p> <p>ASCT2 163</p> <p>Bartholin gland disorders 212</p> <p>Body mass index (BMI) 132</p> <p style="padding-left: 20px;">and antipartum 137</p> <p style="padding-left: 20px;">and congenital anomalies 136</p> <p style="padding-left: 20px;">and fetal macrosomia 136</p> <p style="padding-left: 20px;">and ovulatory disorders 132</p> <p style="padding-left: 20px;">and perinatal mortality 137</p> <p style="padding-left: 20px;">and reproduction of PCO syndrome patients</p> <p style="padding-left: 40px;">outcome 133</p> <p style="padding-left: 20px;">and spontaneous abortion 136</p> <p style="padding-left: 20px;">and still birth 137</p> <p style="padding-left: 20px;">effect on complication of mothers during</p> <p style="padding-left: 40px;">pregnancy 135</p> <p style="padding-left: 20px;">effect on mother on complications of fetus/infant 136</p> <p style="padding-left: 20px;">in amenorrhoea 132</p> <p style="padding-left: 20px;">in anovulatory 132</p> <p style="padding-left: 20px;">in breast cancer 1337</p> <p style="padding-left: 20px;">in endometrial cancer 137</p> <p style="padding-left: 20px;">in menstrual irregularities 132</p> <p style="padding-left: 20px;">in ovulatory controlled ovarian hyperstimulation 132</p> <p style="padding-left: 20px;">long-term complications of 137</p> <p style="padding-left: 20px;">psychological/social effect of 137</p> <p style="padding-left: 20px;">reproduction outcome of 132</p> <p>Body mass index cancer 137</p> <p>Bone mineral density 243</p> <p style="padding-left: 20px;">in healthy young women 243</p> <p>Bone resorption 249</p> <p>Breast cancer 261</p> <p style="padding-left: 20px;">effect of caffeine on 265</p> <p style="padding-left: 20px;">effect of diet on 264</p> <p style="padding-left: 20px;">effect of environment on 267</p> <p style="padding-left: 20px;">effect of genetics on 264</p> <p style="padding-left: 20px;">effect of lifestyle on 265</p> <p style="padding-left: 20px;">effect of methylxanthine on 265</p> <p style="padding-left: 20px;">effect of obesity on 266</p> <p style="padding-left: 20px;">effect of smoking on 266</p> <p>Cancer 79</p> <p style="padding-left: 20px;">preventing HPV infection in 82</p>	<p style="padding-left: 20px;">preventing HPV transmission in 82</p> <p style="padding-left: 20px;">prevention of 82</p> <p style="padding-left: 20px;">role of modifiable cofactors in 82</p> <p style="padding-left: 20px;">screening for 79</p> <p style="padding-left: 20px;">use of Pap test in 79</p> <p>Cervical adenocarcinoma 185</p> <p style="padding-left: 20px;">cold knife conization (CKC) for 187</p> <p style="padding-left: 20px;">endocervical curettage (ECC) for 187</p> <p style="padding-left: 20px;">fertility-sparing surgery for 187</p> <p style="padding-left: 20px;">hysterectomy for 187</p> <p style="padding-left: 20px;"><i>in situ</i> 185</p> <p style="padding-left: 20px;">invasive type 185</p> <p style="padding-left: 20px;">management of 185</p> <p style="padding-left: 20px;">microinvasive (stage IA₁/IA₂) of 188</p> <p style="padding-left: 20px;">post-conization surveillance of 187</p> <p style="padding-left: 20px;">recurrent type 187</p> <p>Cervical cancer 79,99</p> <p style="padding-left: 20px;">barriers to effective screening of 81</p> <p style="padding-left: 20px;">future considerations of 81</p> <p style="padding-left: 20px;">general considerations of 81</p> <p style="padding-left: 20px;">preoperative considerations of 99</p> <p style="padding-left: 20px;">preventing HPV infection in 82</p> <p style="padding-left: 20px;">preventing HPV transmission in 82</p> <p style="padding-left: 20px;">prevention of 79</p> <p style="padding-left: 20px;">role of modifiable cofactors in 82</p> <p style="padding-left: 20px;">screening guidelines for 80</p> <p style="padding-left: 20px;">use of Pap test in 79</p> <p>Cervical dysplasia 82</p> <p style="padding-left: 20px;">preventing HPV infection in 82</p> <p style="padding-left: 20px;">preventing HPV transmission in 82</p> <p style="padding-left: 20px;">prevention of 82</p> <p style="padding-left: 20px;">role of modifiable cofactors in 82</p> <p>Cesarean delivery 171</p> <p style="padding-left: 20px;">cervical dilation at prior 171</p> <p>Chorionic gonadotrophin 201</p> <p>Classical hysterotomy 171</p> <p>Coitus 120</p> <p style="padding-left: 20px;">multiple acts of 120</p> <p style="padding-left: 20px;">selection/ascertainment related to 120</p> <p>Coitus-dependent contraceptive methods 122</p> <p style="padding-left: 20px;">concurrent use of 122</p> <p style="padding-left: 20px;">inappropriate/incomplete administration of 122</p> <p>Complicated pregnancies 226</p> <p style="padding-left: 20px;">maternal allo-reactivity in 226</p> <p>Condoms 151</p> <p style="padding-left: 20px;">effectiveness of 151</p> <p style="padding-left: 20px;">for prevention of sexually transmitted disease 151</p> <p style="padding-left: 20px;">in chlamydia 152</p> <p style="padding-left: 20px;">in genital herpes 156</p> <p style="padding-left: 20px;">in genital human papillomavirus 157</p> <p style="padding-left: 20px;">in gonorrhoea 152</p> <p style="padding-left: 20px;">in pelvic inflammatory disease 157</p> <p style="padding-left: 20px;">in syphilis 152</p> <p style="padding-left: 20px;">in trichomonas 152</p>
---	---

Cytokines	49	(STAR) in.....	90
role of.....	49	role of uridine diphospho(UDP)-	
		glucuronosyltransferase 1A1 in	93
		sex steroid hormone synthesis in	90
Early pregnancy loss (EPL)	136	Endometrial/peripheral T-cells.....	16
and obesity	136	and markers for RSA patients.....	16
Early -stage (IB-IIA) cervical adenocarcinoma.....	190	expression of CD69/SLAM in	16
adjuvant hysterectomy for	191	Endothelial dysfunction	61
clinical trials of	191	action of NO in	61
cone biopsy in	190	contractile response in	61
fertility-sparing surgery for	190	EDHF in.....	61
hysterectomy for.....	190	effect on omental resistance arteries.....	61
laparoscopically-assisted radical vaginal		in preeclampsia	61
hysterectomy (LARVH) for.....	190	reduced production of prostacyclin in	61
lymphadenectomy for	190	role of endothelium-derived hyperpolarizing	
ovarian conservation / transposition for	190	factor in.....	62
postoperative chemo-radiation for.....	191	role of endothelium-derived nitric oxide (NO) in....	62
primary chemo-radiation for.....	191	role of endothelium-derived prostacyclin in	62
radiation therapy for	191	role of endothelium-derived relaxing factors	
radical abdominal hysterectomy for	190	(EDRF) in	61
radical trachelectomy for	190	Endothelium-derived hyperpolarizing factor (EDHF).....	67
Elective cesarean section	85	action of	68
Emergency contraception (EC).....	119	future perspective of	75
and ascertainment of pregnancy status	122	gender differences in mediated responses of	70
approaches used to calculate expected		implication for.....	67
pregnancies by	123	in women's cardiovascular health.....	67
characteristics of women presenting for.....	122	mechanism of release of	68
delay between index intercourse and		mediated responses in normal pregnancy/	
administration of.....	122	preeclampsia	72
effect of inaccurate recall/report of cycle		responses of.....	70
length on	122	role of estrogen in modulating of.....	70
effectiveness of	119		
general approach to estimating effectiveness of.....	119	Female hormonal contraception	105
inclusion in study of	122	development in.....	105,107
methodologic issues in studies of		drug delivery/slow release system of.....	115
effectiveness of	120	drugs from natural products for	114
selection/ascertainment related to.....	120	non-oral	109
Endometrial cancer	89	transdermal technologies for.....	114
and cancer family syndromes	90	Female immun contraceptive vaccine.....	201
androgen receptor in	94	Female reproductive tract.....	35
effect of cytochrome P45011A1 on.....	91	microbiology of.....	35
epidemiology of.....	89	role in pregnancy	35
estrogen metabolism/detoxification in.....	92	toll-like receptor in cycling.....	35
estrogen receptor in	93	Fertility.....	217,218
future directions for	94	assisted reproduction studies in	218
gene-gene/gene-environment interaction for.....	94	effect of intramural/subserosal myomas on	218
genetic susceptibility to	89	effect of submucosal myomas on.....	217
genetic variability in	90	myomectomy studies in	218
hormone receptors in	93	First trimester abortion.....	180
progesterone receptor in	94	Foley bulb.....	173
role of 17 -hydroxysteroid dehydrogenases in	92	Follicular fluid.....	50
role of 3 -hydroxysteroid dehydrogenase in.....	91	cells of immune system in	56
role of catechol- <i>O</i> -methyltransferase in	93	data on cytokine detection in	56
role of cytochrome P45019 in	91	immunoglobulines in	57
role of cytochrome P4501A1 in.....	92	role of interleukins in	50
role of cytochrome P4501B1 in.....	93	Follicular immunology environment.....	49
role of cytochrome P450c17 in.....	91	influence on <i>in vitro</i> fertilization outcome	49
role of hormones in.....	89		
role of steroidogenic acute regulatory protein			

role of chemokines in	53	Immunocontraception	114
role of colony-stimulating factors (CSFS) in	52	Immunomodulator	16
role of epidermal growth factor (EGF) in	54	identification of rantes as	16
role of fibroblast growth factor (FGF) in	54	of maternal allogenic response	16
role of growth factors in	53	Implants	109
role of IFN-like cytokines in	53	Induced abortion	21
role of insulin-like growth factor (IGF) in	54	and substance use	24
role of interferons (IFN) in	53	anger after	26
role of interleukin-10 (IL-10) in	51	anxiety in response to	23
role of interleukin-11 (IL-11) in	51	associated variables of	24
role of interleukin-12 (IL-12) in	52	evidence for association between substance	
role of interleukin-13 (IL-13) in	52	abuse and	22
role of interleukin-18 (IL-18) in	52	future directions for	29
role of interleukin-1 (IL-1) in	50	guilt/self-reproach after	26
role of interleukin-1 (IL-1) in	50	overview of recent studies for	28
role of interleukin-2 (IL-2) in	50	practical implications towards	30
role of interleukin-6 (IL-6) in	50	relationship difficulties after	26
role of interleukin-8 (IL-8) in	51	Inevitable or incomplete abortion	181
role of leukemia inhibitory factor (LIF) in	54	management of	181
role of other interleukins in	52	Infectious diseases	213
role of platelet-derived growth factor (PDGF) in	54	Intrauterine devices	110
role of stem cell factor (SCF) in	54	Labor	170
role of TNF- α -like proteins in	53	induction of	171
role of tumor necrosis factor-alpha (TNF- α) in	53	predictors of trial of	170
role of vascular endothelial growth factor		Labor complications	134
(VEGF) in	53	during pregnancy	134
Galectin-1-mediated apoptotic	15	Laparoscopic pelvic lymphadenectomy	99
induction of allogenic T cell-hyporesponsiveness		fertility preservation with	99
by	15	in treatment of early cervical cancer	99
Gestation-associated disease	231	Lifestyle behaviours	243
HLA molecules for	231	in healthy young women	243
Glial cells missing GCMA	161	Maternofetal tolerance	15
and syncytin	161	Menstrual irregularities	249
effect on human placenta	164	Misoprostol	177
in pre-elampsia	161	contraindication to	180
role in placental health/disease	164	for cervical ripening	180
HELLP-syndrome	227	in fetal demise at term	180
as signs of chronic/acute rejection	227	in premature rupture of membrane (PROM)	
Hormonal age	249	at term	179
Hormonal injection	109	in second trimester termination	182
Hormonal vaginal ring	110	obstetrical applications of	177
Human papillomavirus infection	80	other uses for	183
natural history of	80	pharmacokinetics of	177
Hypoactive sexual desire disorder	143	postpartum use of	182
assessment of	144	Missed abortion	181
clinical evidence of	145	management of	181
diagnosis of	144	Müllerian anomalies	173
estrogen therapy for	148	Mycophenolate mofetil	199
etiology of	143	Myofascial plan	213
impact on quality of life	144		
testosterone therapy for	145		
testosterone therapy options for	147		
treatment after surgical menopause	145		

Non-apoptotic mechanisms.....	15	Pregnancy-associated breast cancer	261
induction of allogenic T cell-hyporesponsiveness		Pregnancy-associated hypertensive diseases.....	226
by	15	inadequate trophoblast invasion in	226
Non-syndrome endometrial cancer.....	90	Pregnancy with renal disease	197
		angiotensin-converting enzyme inhibitor in.....	197
Obesity	137	angiotensin II receptor antagonist in	197
therapy of.....	137	cyclosporine A in.....	198
Oral contraceptive pill.....	105	therapeutic compounds in	197
arterial disease by	111	Pre-invasive disease	79
decreased immunity by	111	barriers in management of	81
development of	107	barriers to effective diagnosis of.....	81
drug delivery/slow release system of.....	115	diagnosis of	81
drugs from natural products.....	114	general considerations of	81
future developments of	113	management of.....	81
health benefits of	113	screening for	79
health risks associated with	111	use of Pap test in	79
health risks of.....	112	Premenopausal women.....	261
historical development of	105	breast cancer risks in	261
hyperkalemia by	112		
neoplasms by	111	Radical vaginal trachelectomy	99
new chemically synthesised hormones as	113	demographics/surgical outcomes of.....	100
non-oral contraceptive side-effects of	112	fertility preservation with.....	99
non-oral methods of.....	113	in treatment of early cervical cancer.....	99
transdermal technologies for	114	oncologic results of.....	101
		pregnancy outcomes of.....	103
Paternal immunization	17	surgical technique of.....	100
modulation of RANTES/CD69/SLAM after.....	17	Recurrent cervical adenocarcinoma	192
of RSA patients.....	17	biologic agent in.....	192
Preeclampsia	226,237	cisplatin in	192
activation of cell of adaptive maternal immune		etoposide in	192
system in	227	paclitaxel in.....	192
activation of cell of innate maternal immune		palliative chemotherapy for	192
system in.....	226	pelvic exenteration for	192
as signs of chronic/acute rejection	227	Reproduction	131
auto-antibodies in	237	relationship with body mass index.....	131
autoimmunity in	240	Riboflavin carrier protein	203
cytokines in	237,238		
dendritic cells in	237,238	Second trimester abortion	182
human leukocyte antigens in	239	Sexual desire	143
immunological aspects of.....	237	assessment of	143
MHC antigens in	237	management of.....	143
role of adhesion molecules in	237	Sexually transmitted diseases (STDs).....	151
Pregnancy.....	36,135,197,225	Sperm antigens	205
angiotensin II receptor antagonist in	197	Stage IA cervical adenocarcinoma.....	189
angiotensin-converting enzyme inhibitor in.....	197	cold knife conization (CKC) for	189
carbohydrate intolerance in	135	extrafascial (type I) hysterectomy for	189
cardiovascular change in	135	fertility-sparing surgery for	189
central / peripheral tolerance induction in	228	hysterectomy for	189
failure in gestation-associated diseases	225	radical (type III) hysterectomy for.....	189
HLA molecules for	231	recurrent adenocarcinoma in	189
infections during	36	Substance abuse	21
lipid disorders in	135	anxiety as mediator of.....	23
local mechanisms of tolerance induction during	228	evidence for association between induced	
mechanisms of tolerance induction	228	abortion and	22
modulation of maternal immune system in	225	future directions for	29
peripheral immune tolerance in	225	in women.....	21
peripheral mechanisms of tolerance induction in ...	231		
pre-eclampsia in.....	135		

methodological issues for	27	Twin-to-twin transfusion syndrome (TTTS).....	43
overview of recent studies for	28	diagnosis of	43,44
practical implications towards	30	etiology of	43
risk of	21	future therapeutic approaches of.....	45
Surgical menopause	143	natural history of.....	44
restoring sexual desire after	143	septostomy for.....	45
Syncytin	161	serial amnioreduction for	44
in pre-eclampsia	161	treatment of	43
regulators in human placental physiology	161	treatment strategies of.....	44
role in placental health and disease	164	use of laser in	45
Syncytin receptor	163		
		Uterine myomas	217
Three-dimensional ultrasound (3D US).....	1	assisted reproduction studies in	218
current status of clinical applications of	2	management of	220
current status of	1	myomectomy studies in	218
future perspectives of.....	1	relationship with infertility.....	217
immunological mechanisms in	15	Uterine rupture	171
in adnexal pathology	9	by classical hysterotomy	171
in congenital uterine anomalies	2	by transverse hysterotomy (kerr)	172
in endometrial cavity	2	by vertical hysterotomy (krönig)	172
in endometrial pathology of postmenopausal		unknown hysterotomies	172
bleeding	2		
in gynecology	1	Vaginal birth.....	169
in sonohysterography.....	2	after cesarean	169
reproducibility of	2	cervical examination in.....	171
technical considerations of	1	effect of birth weight on.....	170
Toll-like receptors (TLR).....	35	effect of gestational or pregestational diabetes on.	171
as clinical marker.....	39	effect of interpregnancy interval on.....	171
at maternal-fetal interface.....	39	effect of maternal characteristics on.....	170
decidual expression of	38	indications for prior cesarean delivery.....	170
expression in fetal membranes	38	obstetric history in	170
expression in placenta.....	38	risk factors for uterine rupture in	171
in non-pregnant reproductive tract	36	use of oxytocin in.....	173
in reproductive tract.....	37	use of prostaglandins in	173
in responses to commensal/pathogenic microbes.....	37	Vulvar dermatoses.....	210
role in innate immune responses	36	Vulvar dysesthesia	214
role in pregnancy	38	Vulvodynia.....	209
signaling of	36	anatomic factors in	209
Transdermal patches	110	dermatological factors in	210
3 rd Trimester.....	177	systematic approach to	209
cervical ripening in	177		
labor induction in.....	177	Weight gain	134
Twin gestations	173	during pre-pregnancy	134